• Je něco špatně v tomto záznamu ?

Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study

A. Thiery-Vuillemin, MH. Poulsen, E. Lagneau, G. Ploussard, A. Birtle, LM. Dourthe, D. Beal-Ardisson, E. Pintus, R. Trepiakas, F. Lefresne, M. Lukac, S. Van Sanden, G. Pissart, A. Reid, AQUARiUS Investigators

. 2020 ; 77 (3) : 380-387. [pub] 20191005

Jazyk angličtina Země Švýcarsko

Typ dokumentu klinické zkoušky, fáze IV, časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020711

BACKGROUND: Few studies have examined patient-reported outcomes (PROs) with abiraterone acetate plus prednisone (abiraterone) versus enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To determine the impact of abiraterone and enzalutamide on PROs. DESIGN, SETTING, AND PARTICIPANTS: AQUARiUS (NCT02813408) was a prospective, 12-mo, observational study in patients with mCRPC from Denmark, France, and the UK. INTERVENTION: Abiraterone or enzalutamide treatment according to routine practise. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PROs were collected over 12 mo using Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), Brief Fatigue Inventory-Short Form (BFI-SF), Brief Pain Inventory-Short Form, and European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire (QLQ-C30) at baseline and routine visits. Outcomes included mean change in PROs, patients with clinically meaningful worsening (CMW) in PROs, and safety. Data were analysed using repeated measures linear and logistic models adjusted for baseline characteristics. RESULTS AND LIMITATIONS: Abiraterone-treated (N = 105) and enzalutamide-treated (N = 106) patients were included. Key PRO items (cognitive impairments and fatigue) were significantly (p < 0.05) in favour of abiraterone versus enzalutamide during the study. "Perceived cognitive impairment" and "comments from others" (FACT-Cog); "fatigue right now", "usual level of fatigue", and "worst level of fatigue" (BFI-SF); and "cognitive functioning" and "fatigue" (QLQ-C30) were significantly in favour of abiraterone over enzalutamide for three or more consecutive periods up to month 12. From study initiation, significantly fewer patients receiving abiraterone experienced one or more CMW episode in cognition and fatigue. Fatigue and asthenia (adverse events) were lower with abiraterone than with enzalutamide (5% vs 15% and 10% vs 11%, respectively). There were no treatment-related deaths. Limitations included lack of randomisation. CONCLUSIONS: In a real-world setting, this 12-mo analysis suggests an advantage of abiraterone acetate plus prednisone over enzalutamide on fatigue and cognitive function; this finding occurred early after treatment initiation. This difference should be considered when choosing treatment. PATIENT SUMMARY: This study looked at the effect of two treatments (abiraterone acetate plus prednisone and enzalutamide) for metastatic castration-resistant prostate cancer on patient quality of life over 12 mo. Using established questionnaires, patients reported that they experienced less fatigue and cognitive impairments (including memory loss and reduced thinking abilities) with abiraterone acetate plus prednisone than with enzalutamide.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020711
003      
CZ-PrNML
005      
20210830102330.0
007      
ta
008      
210728s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eururo.2019.09.019 $2 doi
035    __
$a (PubMed)31594705
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Thiery-Vuillemin, Antoine $u Department of Medical Oncology, CHU Jean Minjoz, Franche-Comté, France; UMR1098, INSERM, Besançon, France. Electronic address: a.thieryvuillemin@mac.com
245    10
$a Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study / $c A. Thiery-Vuillemin, MH. Poulsen, E. Lagneau, G. Ploussard, A. Birtle, LM. Dourthe, D. Beal-Ardisson, E. Pintus, R. Trepiakas, F. Lefresne, M. Lukac, S. Van Sanden, G. Pissart, A. Reid, AQUARiUS Investigators
520    9_
$a BACKGROUND: Few studies have examined patient-reported outcomes (PROs) with abiraterone acetate plus prednisone (abiraterone) versus enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To determine the impact of abiraterone and enzalutamide on PROs. DESIGN, SETTING, AND PARTICIPANTS: AQUARiUS (NCT02813408) was a prospective, 12-mo, observational study in patients with mCRPC from Denmark, France, and the UK. INTERVENTION: Abiraterone or enzalutamide treatment according to routine practise. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PROs were collected over 12 mo using Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), Brief Fatigue Inventory-Short Form (BFI-SF), Brief Pain Inventory-Short Form, and European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire (QLQ-C30) at baseline and routine visits. Outcomes included mean change in PROs, patients with clinically meaningful worsening (CMW) in PROs, and safety. Data were analysed using repeated measures linear and logistic models adjusted for baseline characteristics. RESULTS AND LIMITATIONS: Abiraterone-treated (N = 105) and enzalutamide-treated (N = 106) patients were included. Key PRO items (cognitive impairments and fatigue) were significantly (p < 0.05) in favour of abiraterone versus enzalutamide during the study. "Perceived cognitive impairment" and "comments from others" (FACT-Cog); "fatigue right now", "usual level of fatigue", and "worst level of fatigue" (BFI-SF); and "cognitive functioning" and "fatigue" (QLQ-C30) were significantly in favour of abiraterone over enzalutamide for three or more consecutive periods up to month 12. From study initiation, significantly fewer patients receiving abiraterone experienced one or more CMW episode in cognition and fatigue. Fatigue and asthenia (adverse events) were lower with abiraterone than with enzalutamide (5% vs 15% and 10% vs 11%, respectively). There were no treatment-related deaths. Limitations included lack of randomisation. CONCLUSIONS: In a real-world setting, this 12-mo analysis suggests an advantage of abiraterone acetate plus prednisone over enzalutamide on fatigue and cognitive function; this finding occurred early after treatment initiation. This difference should be considered when choosing treatment. PATIENT SUMMARY: This study looked at the effect of two treatments (abiraterone acetate plus prednisone and enzalutamide) for metastatic castration-resistant prostate cancer on patient quality of life over 12 mo. Using established questionnaires, patients reported that they experienced less fatigue and cognitive impairments (including memory loss and reduced thinking abilities) with abiraterone acetate plus prednisone than with enzalutamide.
650    _2
$a abirateron $x aplikace a dávkování $7 D000069501
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protinádorové látky $x aplikace a dávkování $7 D000970
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    _2
$a benzamidy $x aplikace a dávkování $7 D001549
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a nitrily $x aplikace a dávkování $7 D009570
650    12
$a hodnocení výsledků péče pacientem $7 D000071066
650    _2
$a fenylthiohydantoin $x aplikace a dávkování $7 D010669
650    _2
$a prednison $x aplikace a dávkování $7 D011241
650    _2
$a prospektivní studie $7 D011446
650    _2
$a nádory prostaty rezistentní na kastraci $x farmakoterapie $x patologie $7 D064129
650    _2
$a časové faktory $7 D013997
655    _2
$a klinické zkoušky, fáze IV $7 D017429
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Poulsen, Mads Hvid $u Department for Urology, Odense Hospital, Odense, Denmark; Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark
700    1_
$a Lagneau, Edouard $u Oncologie Medicale, Institut de Cancérologie de Bourgogne, Dijon, France
700    1_
$a Ploussard, Guillaume $u Urologie, Clinique La Croix du Sud, Quint Fonsegrives, France
700    1_
$a Birtle, Alison $u Royal Lancaster Infirmary and Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK
700    1_
$a Dourthe, Louis-Marie $u Cancerologie, Clinique Sainte Anne, Strasbourg, France
700    1_
$a Beal-Ardisson, Dominique $u Cancerologie, Hôpital privé Jean Mermoz, Lyon, France
700    1_
$a Pintus, Elias $u Oncology, Frimley Health NHS Foundation Trust, Slough, UK
700    1_
$a Trepiakas, Redas $u Oncology, Zealand University Hospital, Naestved, Denmark
700    1_
$a Lefresne, Florence $u EMEA Oncology, Janssen Pharmaceutica NV, Beerse, Belgium
700    1_
$a Lukac, Martin $u Parexel International Czech Republic s.r.o, on behalf of Janssen Pharmaceutica NV, Beerse, Belgium
700    1_
$a Van Sanden, Suzy $u EMEA Oncology, Janssen Pharmaceutica NV, Beerse, Belgium
700    1_
$a Pissart, Genevieve $u EMEA Oncology, Janssen Pharmaceutica NV, Beerse, Belgium
700    1_
$a Reid, Alison $u Academic Uro-Oncology Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
710    2_
$a AQUARiUS Investigators
773    0_
$w MED00001669 $t European urology $x 1873-7560 $g Roč. 77, č. 3 (2020), s. 380-387
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31594705 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102330 $b ABA008
999    __
$a ok $b bmc $g 1691316 $s 1141157
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 77 $c 3 $d 380-387 $e 20191005 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace